RxDoctor Payments Data

Heather Vasser, MD

Surgery · Columbus, TXNPI 1528398609

Payments from drug & device makers

$1,017in general payments, 2019–2025

Across 53 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$316
  • Endogastric Solutions, Inc$125
  • Phathom Pharmaceuticals, Inc.$99
  • Myriad Genetic Laboratories, Inc.$74
  • Braintree Laboratories, Inc.$74
  • Microline Surgical Inc$56
  • plus $272 from 11 others

What the payments were for

  • Food & beverage$1,00098%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,017 in reported general payments places this provider in the 35th percentile of 1,830 surgery providers in Texas.

See all surgery providers in Texas

Medicare billing

Part B allowed, 2024
$288,986
Medicare patients
825
Services billed
1,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide61$34,090
Pantoprazole Sodium1,282$11,820
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates154$10,001
Dexlansoprazole DrDexlansoprazole43$8,272
Famotidine845$6,463
SutabSod Sulf/Pot Chloride/Mag Sulf37$5,946
Mesalamine25$5,173
Colestipol Hcl134$4,786
Omeprazole492$3,975
Sucralfate194$3,951
Balsalazide Disodium32$2,580
CholestyramineCholestyramine (With Sugar)25$1,769
Dicyclomine Hcl45$654
Linezolid11$634
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen93$471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$316$34,09061 claims
Braintree Laboratories, Inc.Sutab$74$5,94637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,830 surgery providers in Texas.

Other surgery in Columbus

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →